Trials / Completed
CompletedNCT07034768
A Study to Evaluate EDG-7500 in People With Renal Impairment
A Phase 1, 2-Part, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Edgewise Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EDG-7500 | Single dose of EDG-7500 |
Timeline
- Start date
- 2025-07-22
- Primary completion
- 2025-12-22
- Completion
- 2025-12-26
- First posted
- 2025-06-24
- Last updated
- 2026-03-12
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07034768. Inclusion in this directory is not an endorsement.